



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

TPO agonist 1

Cat. No.:	HY-100380
CAS No.:	1033040-23-1
Molecular Formula:	C ₂₅ H ₂₂ N ₈ O ₂
Molecular Weight:	466.49
Target:	Thrombopoietin Receptor
Pathway:	Immunology/Inflammation
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 36 mg/mL (77.17 mM)
 * "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		2.1437 mL	10.7183 mL	21.4367 mL
	5 mM		0.4287 mL	2.1437 mL	4.2873 mL
	10 mM		0.2144 mL	1.0718 mL	2.1437 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2 mg/mL (4.29 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2 mg/mL (4.29 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

TPO agonist 1 is a thrombopoietin (TPO) agonist extracted from patent WO2008134338A1, compound TPO mimetic. It would be useful as promoters of thrombopoiesis and megakaryocytopoiesis to treat thrombocytopenia^[1].

IC₅₀ & Target

TPO receptor^[1]

In Vivo

The thrombopoietin (TPO) receptor agonists are novel treatments for patients with chronic ITP aimed at increasing platelet production through interactions with the TPO receptor on megakaryocytes, and can increase platelet counts, decrease bleeding events and reduce the need for adjunctive or rescue treatments. The TPO receptor agonists are well-tolerated, though uncertainty remains regarding the risk of thromboembolism and bone marrow fibrosis^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Jerome Francis Hayes. Novel processes of making hydroxy-1-azo-derivatives as tpo mimetics. 6 November 2008. WO2008134338A1.
- [2]. Siegal D et al. Thrombopoietin receptor agonists in primary immune thrombocytopenia. et al. Semin Hematol. 2013 Jan;50 Suppl 1:S18-21
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA